Sionna Therapeutics Posts Larger-than-Expected Quarterly Loss

Summary

Sionna Therapeutics (NASDAQ: SION) reported a quarterly loss of ($0.62) per share, exceeding the market consensus expectation of a ($0.45) loss per share, with a difference of ($0.17). The stock opened at $12.32, with a 52-week range of $7.26 to $25.19. Analysts have begun coverage with a ‘buy’ rating and target prices of $45.00 and $32.00. The company focuses on developing treatments for cystic fibrosis by normalizing CFTR protein function. Market Beat

Impact Analysis

1. Business Overview Analysis: